CLEAR+BRILLIANT LASER SYSTEM
K110349 · Solta Medical, Inc. · ONG · May 3, 2011 · General, Plastic Surgery
Device Facts
| Record ID | K110349 |
| Device Name | CLEAR+BRILLIANT LASER SYSTEM |
| Applicant | Solta Medical, Inc. |
| Product Code | ONG · General, Plastic Surgery |
| Decision Date | May 3, 2011 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 878.4810 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Intended Use
Dermatological procedures requiring the coagulation of soft tissue and general skin resurfacing procedures.
Device Story
The CLEAR+BRILLIANT™ Laser System is a non-ablative laser for non-invasive dermatological procedures. It consists of a console and a handpiece containing a laser source controlled by an embedded processor. Laser energy is delivered to tissue via disposable contact treatment tips. The system utilizes an optical tracking system to create a pattern of micro-treatment zone punctures. It is operated at pre-determined energy settings rather than user-selectable settings. The device is used by clinicians in a professional setting to perform skin resurfacing and soft tissue coagulation, potentially benefiting patients through non-invasive skin rejuvenation.
Clinical Evidence
Bench testing only. Evidence includes compliance with ISO 60601-1 (electrical safety), IEC 60601-1-2 (EMI/EMC), ISO 60825 (laser safety), and ISO 10993-1 (biocompatibility). Histological analysis confirmed that the treatment skin response is equivalent to the predicate Fraxel IV SR laser system when used at comparable energy density settings.
Technological Characteristics
Non-ablative laser system; embedded processor control; disposable contact treatment tips. Compliant with ISO 60601-1, IEC 60601-1-2, ISO 60825, and ISO 10993-1. Features an optical tracking system for fractional treatment patterns. Operates at fixed, pre-determined energy settings.
Indications for Use
Indicated for dermatological procedures requiring coagulation of soft tissue and general skin resurfacing in patients requiring such dermatological care.
Regulatory Classification
Identification
(1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
Predicate Devices
- Fraxel IV SR Laser System (K063808)
Related Devices
- K120433 — CLEAR + BRILLIANT LASER SYSTEM · Solta Medical, Inc. · Apr 2, 2012
- K223647 — CLEAR+BRILLIANT TOUCH® Laser System · Solta Medical, Inc. · Dec 29, 2022
- K192350 — Medical Non-Ablative Fractional Laser Systems · Wingderm Electro-Optics , Ltd. · Apr 30, 2020
- K233803 — UltraClear Laser System (N/A) · Acclaro Corporation · May 8, 2024
- K252155 — AVAVA Skin Treatment System · AVAVA, Inc. · Oct 20, 2025
Submission Summary (Full Text)
{0}------------------------------------------------
K110349
# 510(k) SUMMARY STATEMENT
MAY - 3 2011
This 510(k) summary is being submitted in accordance with the requirements of the Safe Medical Devices Act of 1990, 21 CFR 807.92
# 1. General Information
Date of Submission: February 4, 2011
Submitted By:
Solta Medical, Inc. 25881 Industrial Blvd Hayward, CA 94545
Contact Person:
Kristine Foss V.P., Regulatory, Clinical & Quality 510-780-4657 (Direct Phone) 510-780-4857 Fax kfoss@solta.com
## 2. Trade/Proprietary Name of Device:
| Trade Name: | CLEAR+BRILLIANTT™ Laser System |
|------------------------|-------------------------------------|
| Common Name: | Laser Surgical Instrument |
| Regulation Number | 878.4810 |
| Product Code: | GEX |
| Device Panel: | General Surgery/Restorative Devices |
| Device Classification: | Class II |
# 3. Legally Marketed Predicate Device for Claimed Equivalence:
Name: Fraxel IV SR Laser System 510(k) #: K063808
#### 4. Device Description
The CLEAR+BRILLIANT™ Laser System is a non-ablative laser system designed for use in non-invasive dermatological procedures.
The CLEAR+BRILLIANT™ Laser System has a laser source in the hand piece which is controlled by an embedded processor. The console is electrically connected to the facility power source. Laser energy produced by the unit is delivered to the tissue through the removable (disposable) contact treatment tips which attach to the hand piece.
## 4. Indications for Use:
Dermatological procedures requiring the coagulation of soft tissue and general skin resurfacing procedures.
{1}------------------------------------------------
# ડ. Technological Performance Data:
The CLEAR+BRILLIANT™ Laser System is compliant with ISO 60601-1 for electrical safety, IEC 60601-1-2 for EMI/EMC, ISO 60825 and 10993-1 for biocompatibility of the treatment tips.
Histology confirms the treatment skin response is the same as for the predicate Fraxel IV SR laser system when used at the same energy density settings.
The difference between the CLEAR+BRILLIANT™ device and its predicate is that the CLEAR+BRILLIANT™ device is operated at pre-determined energy settings (the lower end of the range in the predicate); not user selectable settings, as in the predicate.
## ર્. Summary Statement:
With the same intended use, same patient population, same setting (wavelength, spot-size, fractional treatment and pattern of micro treatment zone punctures, same optical tracking system, and histological ooutcome), the CLEAR+BRILLIANT™ laser system is equivalent to the Fraxel IV SR laser system. Based upon the passing test results for laser safety and electrical safety, as well as biocompatibility and histology, when compared to the predicate, the CLEAR+BRILLIANT™ laser raises no new safety and effectiveness questions.
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with three stripes forming its body and wings. The eagle is facing right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
MAY - 3 2011
Solta Medical, Inc. % Ms. Kristine Foss V.P., Regulatory, Clinical & Quality 25881 Industrial Boulevard Hayward, California 94545
Re: K110349
Trade/Device Name: CLEAR+BRILLIANT™ Laser System Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: II Product Code: ONG Dated: April 5, 2011 Received: April 7, 2011
Dear Ms. Foss:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act
{3}------------------------------------------------
Page 2 - Ms. Kristine Foss
or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act s requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801): medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act): 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.lda.gov/Mcdicall.cvices/Safetv/ReportalProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Mark N. Molkerson
Mark N. Melkerson Director Division of Surgical. Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
. -Enclosure
{4}------------------------------------------------
# Indications for Use
510(k) Number (if known): _ KII 0349
CLEAR+BRILLIANT™ Laser System Device Name:
Indications For Use:
Dermatological procedures requiring the coagulation of soft tissue and general skin resurfacing procedures.
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
> Concurrence of C te of Device Evaluation (ODE)
J.R. M. Sale for mkn
(Division Sign-Off)
Division of Surgical, Orthopedic, and Restorative Devices
510(k) Number K110349
Page 1 of 1
10